A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome

Blood

Volumn 108, Issue 1, 2006, Pages 97-102

  Coustan Smith, Elaine ^b   Ribeiro, Raul C ^b   Stow, Patricia ^b   Zhou, Yinmei ^b   Pui, Ching Hon ^b   Rivera, Gaston K ^b   Pedrosa, Francisco ^b   Campana, Dario ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; CD19 ANTIGEN; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ASSAY; BONE MARROW; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER RISK; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOBLAST; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STEM CELL; UNIVARIATE ANALYSIS;

EID: 33745622137     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-0066     Document Type: Article

References (39)

1. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia: current status and future perspectives. Lancet Oncol. 2001;2:597-607.
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-1548.
3. Riehm H, Reiter A, Schrappe M, et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Paediatr. 1987;199:151-160.
4. Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after 1 week of multi-agent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995;86:1292-1295.
5. Lilleyman JS, Gibson BE, Stevens RF, et al. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin: The Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol. 1997;97:603-606.
6. Schrappe M, Arico M, Harbott J, et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 1998;92:2730-2741.
7. Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94:1209-1217.
8. Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol. 1989;7:1807-1815.
9. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia: the importance of early marrow response: report from the Childrens Cancer Group [see comments]. J Clin Oncol. 1996;14:389-398.
10. Sandlund JT, Harrison PL, Rivera G, et al. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood. 2002;100:43-47.
11. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol. 2001;2:409-417.
12. Campana D. Determination of minimal residual disease in leukemia patients. Br J Haematol. 2003;121:823-838.
13. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods. 2000;243:59-75.
14. Raimondi SC, Mathew S, Pui CH. Cytogenetics as a diagnostic aid for childhood hematological disorders: conventional cytogenetic techniques, fluorescence in situ hybridization, comparative genomic hybridization. In: Hanausek M, Walaszek Z, eds. Methods in Molecular Biology. Totowa NJ: Humana Press; 1998:209-227.
15. Scurto P, Hsu RM, Kane JR, et al. A multiplex RT-PCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia. Leukemia 1998;12:1994-2005.
16. Cheok MH, Yang W, Pui CH, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet. 2003;34:85-90.
17. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-2696.
18. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
19. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550-554.
20. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691-2696.
21. Neale GA, Coustan-Smith E, Pan Q, et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 1999;13:1221-1226.
22. Neale GA, Coustan-Smith E, Stow P, et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2004;18:934-938.
23. Sykes PJ, Neoh SH, Brisco MJ, et al. Quantitation of targets for PCR by use of limiting dilution. Biotechniques. 1992;13:444-449.
24. Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf TF. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia. 1995;9:321-328.
25. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
26. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
27. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998-1006.
28. Rubnitz JE, Downing JR, Pui CH, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol. 1997;15:1150-1157.
29. Lorenzana R, Coustan-Smith E, Antillon F, Ribeiro RC, Campana D. Simple methods for the rapid exchange of flow cytometric data between remote centers. Leukemia. 1999;14:336-337.
30. Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA. 2004;291:2471-2475.
31. Silverman LB, Sallan SE. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol. 2003;10:290-296.
32. Cave H, Guidal C, Rohrlich P, et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood. 1994;83:1892-1902.
33. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731-1738.
34. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.
35. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100:52-58.
36. Eden T. Translation of cure for acute lymphoblastic leukaemia to all children. Br J Haematol. 2002;118:945-951.
37. Ribeiro RC, Pui CH. Saving the children: improving childhood cancer treatment in developing countries. N Engl J Med. 2005;352:2158-2160.
38. Pui CH, Aur RJ, Bowman WP, et al. Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia. Cancer Res. 1984;44:3593-3598.
39. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000;18:1508-1516.